Cancer Biological Therapy Market By Therapy Type (Monoclonal Antibodies, Cancer Vaccines, Cytokines & Interleukins, Gene Therapy, Oncolytic Virus Therapy), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer), By End-User (Hospitals, Clinics, Research Institutes), By Route of Administration (Intravenous, Subcutaneous, Oral), and By Mechanism of Action (Immune Checkpoint Inhibitors, Targeted Therapy, CAR-T Cell Therapy, Cancer Vaccines); Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Cancer Biological Therapy Market was valued at USD 25.9 Billion in 2024-e and will surpass USD 86.9 Billion by 2030; growing at a CAGR of 22.4% during 2025-2030.

The global cancer biological therapy market is witnessing significant growth due to rising cancer incidences, advancements in immunotherapy, and increasing demand for targeted treatments. This market includes a range of therapies such as monoclonal antibodies, cancer vaccines, cytokines, and gene therapy, all designed to leverage the body's immune system or target cancer cells more effectively. With increasing research and development, the market continues to expand, driven by technological advancements and higher healthcare expenditures.

Monoclonal Antibodies Segment Is Largest Owing to Their Versatility

Monoclonal antibodies (mAbs) have emerged as the largest and most widely used therapy type in cancer treatment. These lab-made molecules mimic the immune system’s ability to fight harmful pathogens such as viruses and bacteria. mAbs are used in treating several cancer types, including breast cancer, lung cancer, and colorectal cancer, due to their ability to specifically target and bind to cancer cells. The increasing adoption of mAbs is attributed to their proven efficacy, particularly in targeted cancer therapies. This segment has seen the launch of numerous blockbuster therapies, including Herceptin for breast cancer and Rituxan for lymphoma, positioning monoclonal antibodies as a critical component of modern oncology treatments.

The growth in monoclonal antibody therapies is further supported by the growing number of pipeline drugs in development, with several targeting novel cancer types and mutations. Additionally, the approval of biosimilars for mAbs has reduced treatment costs, making these therapies more accessible. As such, the demand for monoclonal antibodies is expected to continue to rise, with strong clinical outcomes and ongoing R&D driving their dominance in the cancer biological therapy landscape.

Lung Cancer Segment Is Fastest Growing Owing to Increasing Incidence Rates

Lung cancer is rapidly becoming the fastest-growing cancer type treated by biological therapies. It is one of the most common and deadly cancers globally, which increases the demand for innovative treatments. The application of immunotherapies, particularly immune checkpoint inhibitors like Keytruda and Opdivo, has revolutionized lung cancer treatment. These therapies work by enhancing the body’s immune system to identify and destroy cancer cells, offering an effective alternative to traditional treatments like chemotherapy and radiation.

Lung cancer treatment is further propelled by the growing number of clinical trials and approval of advanced therapies that target specific mutations, such as EGFR and ALK inhibitors. As early detection methods improve and targeted therapies become more effective, the lung cancer segment is poised for continued growth. With the rising incidence of lung cancer, particularly in developing regions, this segment will likely maintain its rapid expansion within the cancer biological therapy market.

Hospitals Are the Largest End-User Segment for Cancer Biological Therapy

Hospitals are the largest end-user segment in the cancer biological therapy market, owing to their central role in cancer treatment and care. Hospitals are the primary facilities where patients undergo advanced cancer therapies, including chemotherapy, radiotherapy, and biologic treatments. These institutions typically have the infrastructure, skilled professionals, and specialized equipment to administer complex treatments like monoclonal antibodies and immunotherapy.

Moreover, hospitals are preferred by patients for the access they provide to comprehensive cancer care, including diagnostics, surgeries, and post-treatment care. The ability to handle critical cancer cases and offer integrated treatment plans drives the dominance of hospitals in the end-user segment. This trend is expected to continue as healthcare systems evolve to offer advanced therapies that require specialized care and monitoring, further cementing hospitals' pivotal role in the cancer biological therapy market.

Intravenous Administration Segment Is Largest Owing to Its Efficacy

Intravenous (IV) administration is the largest route of administration for cancer biological therapies. This method ensures that biologic drugs are delivered directly into the bloodstream, allowing for faster and more efficient absorption. Intravenous infusion is especially beneficial for therapies like monoclonal antibodies and cytokines, which may require precise and controlled administration to achieve optimal efficacy. The rapid onset of action associated with intravenous administration contributes to its dominance in cancer biological therapy.

Additionally, intravenous administration is the preferred method in clinical settings where healthcare providers can closely monitor patients for potential side effects or allergic reactions. This administration route is particularly crucial in treating advanced cancers where quick therapeutic intervention is necessary. As new biologic therapies continue to emerge, the intravenous segment will maintain its leadership position due to the clinical efficacy and practicality it offers in delivering targeted cancer treatments.

Immune Checkpoint Inhibitors Segment Is Fastest Growing Due to Their Effectiveness

Immune checkpoint inhibitors are rapidly emerging as the fastest-growing mechanism of action in cancer biological therapy. These inhibitors work by blocking the proteins that prevent immune cells from attacking cancer cells, allowing the immune system to fight tumors more effectively. The approval of immune checkpoint inhibitors like PD-1/PD-L1 inhibitors, such as Keytruda and Opdivo, has significantly changed the treatment landscape for cancers like melanoma, lung cancer, and bladder cancer.

The growing adoption of immune checkpoint inhibitors is driven by their impressive efficacy in treating a variety of cancers, coupled with the development of combination therapies that enhance their effectiveness. With ongoing clinical trials and the expansion of indications for these drugs, the immune checkpoint inhibitors segment is set to maintain its rapid growth. The increasing number of patients benefiting from these therapies, combined with expanding research, positions immune checkpoint inhibitors as a cornerstone of modern oncology treatments.

North America Is the Largest Region in Cancer Biological Therapy Market

North America is the largest region in the cancer biological therapy market, driven by high healthcare spending, advanced healthcare infrastructure, and strong adoption of cutting-edge therapies. The United States, in particular, is home to a large number of biotech companies and research institutions that are at the forefront of cancer research and therapy development. Additionally, the regulatory environment in North America supports the rapid approval and commercialization of new cancer therapies, further boosting market growth.

Moreover, North America has one of the highest cancer incidences globally, prompting significant demand for innovative cancer treatments. The increasing focus on personalized medicine, targeted therapies, and immunotherapies is expected to sustain the region's dominance. As cancer treatment continues to evolve, North America will remain a key player in the global cancer biological therapy market.

Competitive Landscape and Leading Companies

The cancer biological therapy market is highly competitive, with several leading companies driving innovation and market expansion. Key players include Amgen, Bristol Myers Squibb, Roche, Merck & Co., and Gilead Sciences, all of which have extensive portfolios of cancer therapies, including monoclonal antibodies and immune checkpoint inhibitors. These companies are heavily invested in research and development to discover novel therapies and maintain their market leadership.

The competitive landscape is characterized by frequent mergers, acquisitions, and partnerships, as companies aim to expand their product offerings and gain access to new technologies. Additionally, with increasing demand for personalized and targeted treatments, collaborations between pharmaceutical companies and biotechnology firms are becoming more common. As the market continues to evolve, companies will focus on expanding their pipeline, gaining regulatory approvals, and addressing unmet needs in cancer therapy to stay competitive in the rapidly growing oncology market.

List of Leading Companies:

• Amgen
• Bristol Myers Squibb
• Roche
• Merck & Co.
• Novartis
• Gilead Sciences
• Eli Lilly and Co.
• Regeneron Pharmaceuticals
• Sanofi
• Pfizer
• AstraZeneca
• Johnson & Johnson
• GlaxoSmithKline
• Celgene Corporation (Bristol Myers Squibb)
• Bayer AG

Recent Developments:

• Bristol Myers Squibb announced the FDA approval of a new monoclonal antibody therapy for lung cancer, significantly expanding their oncology portfolio.
• Merck & Co. completed a merger with a leading biotech firm, boosting their immunotherapy pipeline for the treatment of various cancers.
• Amgen launched a next-generation cancer vaccine aimed at treating colorectal cancer, marking a major step forward in preventive cancer treatment.
• Regeneron Pharmaceuticals received regulatory approval for a new cytokine therapy for blood cancer, aiming to improve patient outcomes in relapsed cases.
• Novartis unveiled a promising new CAR-T cell therapy for pediatric leukemia, highlighting the company's continued commitment to pediatric oncology advancements

Report Scope: